Table 1.
Baseline Characteristics.
| No Prophylactic Tocilizumab (n = 15) | Prophylactic Tocilizumab (n = 38) | MajesTEC-1 (N = 165) [2] | |
|---|---|---|---|
| Median Age, years, (range) | 58 (47–73) | 69 (43–83) | 64 (33–84) |
| Male, n (%) | 13 (86.7) | 25 (65.8) | 96 (58.2) |
| Race, n (%) | |||
| White | 7 (46.7) | 18 (47.4) | 134 (81.2) |
| Black/African American | 8 (53.3) | 16 (42.1) | 21 (12.7) |
| Hispanic | — | 3 (7.8) | |
| Asian | — | 1 (2.6) | 3 (1.8) |
| Other | — | 3 (7.9) | 7 (4.2) |
| ISS Stage at Diagnosis, n (%)a | |||
| I | 2 (22.2) | 14 (36.8) | 85 (52.5) |
| II | 2 (22.2) | 8 (21.1) | 57 (35.2) |
| III | 5 (55.6) | 15 (39.5) | 20 (12.3) |
| High Risk Cytogenetics | 4 (26.7) | 17 (44.7) | 38/148 (25.7) |
| BMPCsb | |||
| ≤5% | 13 (34.2) | ||
| ≤30% | 111 (67.3) | ||
| 6–60% | 5 (13.2) | ||
| 30–60% | 31 (18.8) | ||
| ≥60% | 8 (4.8) | ||
| 61–90% | 7 (18.4) | ||
| > 90% | 2 (5.3) | ||
| Not Assessable | 11 (28.9) | ||
| > 1 Extramedullary Plasmacytomab | 14 (37) | 28 (17) | |
| Median Prior Lines of Therapy, (range) | 6 (4–14) | 5 (2–13) | 5 (2–14) |
aSix patients in no prophylaxis cohort and one patient in prophylaxis cohort with whose ISS stage could not be assessed; In MajesTEC-1, three patients with whose ISS not assessed.
bBone marrow plasma cells (BMPCs) and extramedullary disease were not assessed in no prophylactic tocilizumab cohort due to change in practice around the time of prophylactic tocilizumab initiation.